Liposomal Asiaticoside 40% Enhanced Absorption Centella Asiatica Triterpenoid Powder

Product Detailed Description

liposomal Asiaticoside 40% — High Bioavailability Collagen Synthesis and Skin Repair Supplement

Product Overview

Liposomal Asiaticoside 40% is a premium-grade dietary supplement ingredient delivering asiaticoside in an advanced liposomal delivery system. Asiaticoside (CAS 16830-15-2), also known as madecassol, asiaticoside A, or urs-12-en-28-oic acid, is a pentacyclic triterpenoid saponin with the molecular formula C₄₈H₇₈O₁₉ and a molecular weight of 959.13 g/mol. It occurs as a white to off-white crystalline powder with a melting point of 234°C and is practically insoluble in water (99 mg/L at 20°C) but soluble in ethanol, methanol, and pyridine.

Asiaticoside is the major bioactive triterpenoid glycoside of Centella asiatica (L.) Urban, a herbaceous plant widely used in traditional Chinese and Ayurvedic medicine for wound healing and skin health. The active constituents of Centella asiatica include asiatic acid, madecassic acid, asiaticoside, and madecassoside. Among these, asiaticoside is the most extensively studied for its collagen-stimulating and tissue-remodeling properties. It is naturally present in the leaves of Centella asiatica, with reported contents ranging from 0.4% to 8.0% w/w depending on the plant source and cultivation conditions, while elite accessions from southern India and the Andaman Islands have demonstrated asiaticoside contents up to 1.70 ± 0.02% dry weight.

Why Liposomal Technology?

Conventional asiaticoside presents significant formulation challenges. The compound has a large molecular weight of approximately 959 g/mol and is both poorly water-soluble and poorly liposoluble, making it extremely difficult to permeate biological barriers such as the intestinal epithelium and the stratum corneum of the skin. Oral administration of Centella asiatica total glucosides (CTG) failed to fulfill their therapeutic potential due to the low bioavailability of asiaticoside.

Liposomal encapsulation provides four critical advantages:

1. Significantly Enhanced Intestinal Absorption — CTG-loaded liposomes were prepared using the ethanol injection method to enhance intestinal absorption of asiaticoside. The cumulative absorption amount (Q) and cumulative absorption percentage (P%) of asiaticoside in the CTG-loaded liposome were significantly higher than in unencapsulated CTG (P < 0.05). The liposomes exhibited an average particle size of 137.0 nm with a polydispersity index of 0.283 and a zeta potential of −21.2 mV, indicating good physical stability.

2. Enhanced Skin Penetration and Permeation — Asiaticoside liposome gel achieved a drug encapsulation rate of 90.80% with good percutaneous permeation and absorption performance. The flexible nano liposome gel formulation demonstrated a steady-state transdermal permeation rate of 16.15 μg·cm⁻²·h⁻¹ with an intradermal retention of 14.99 ± 0.58 μg/cm², significantly higher than conventional asiaticoside gel formulations. Patent literature confirms that liposomal encapsulation enhances the skin penetrability of asiaticoside, which otherwise can hardly permeate the skin due to its high molecular weight and poor solubility.

3. Improved Structural Stability — TEM imaging of CTG-loaded liposomes showed round, structurally intact vesicles, and DSC thermograms indicated that the CTG molecules were incorporated into the aqueous phase of DPPC liposomes, becoming more stable as a result.

4. Sustained Release Profile — Asiaticoside polymeric nanoparticles demonstrated a sustained release profile up to 24 hours in comparison to free asiaticoside, which was completely released within 6 hours, and exhibited enhanced intracellular uptake in fibroblasts within 3 hours compared to the free drug. Liposomal encapsulation similarly provides a controlled-release matrix that prolongs the biological activity of asiaticoside.

Product Specifications

Key Features

High Purity — Standardized to ≥40% asiaticoside by HPLC, with ≥95% assay available for premium applications.

Liposomal Enhancement — CTG-loaded liposomes achieve an average particle size of 137.0 nm with significantly enhanced intestinal absorption compared to unencapsulated asiaticoside (P < 0.05).

Collagen Synthesis Stimulation — Asiaticoside induces type I collagen synthesis in human dermal fibroblasts and promotes fibroblast proliferation and extracellular matrix synthesis. Type I secreted collagen increased by 25–30% in cultured human fibroblasts treated with asiaticoside.

Wound Healing and Angiogenesis — Asiaticoside has wound curative ability by increasing angiogenesis and collagen formation. Topical use of a 0.2% asiaticoside solution resulted in an increase in collagen content and a 57% increase in tensile strength.

Anti-Inflammatory Activity — Asiaticoside suppresses inflammatory responses through inhibition of NF-κB p65 subunit phosphorylation and IκBα degradation, reducing pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β while increasing anti-inflammatory IL-10.

Clinically Studied — Clinical trials have evaluated Centella asiatica extracts containing asiaticoside for wound healing, scar recovery, and skin health, with studies demonstrating shortened healing times and improved recovery in various wound types including diabetic ulcers and burns.

Water-Dispersible — Liposomal powder offers excellent dispersibility in aqueous systems; suitable for capsules, tablets, powder drink mixes, and functional beverages.

Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Commercial Centella asiatica supplements standardized to asiaticoside typically provide 15–400 mg of asiaticoside per daily dose depending on the product format and intended application. Standardized extracts generally contain 20% asiaticosides, with daily doses ranging from 1–3 capsules providing 80–1,200 mg of extract, corresponding to approximately 16–240 mg of asiaticoside. For general skin health and collagen support, 20–40 mg of asiaticoside daily is commonly used. For wound healing and anti-inflammatory applications, higher doses of 40–80 mg daily may be appropriate. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability, as demonstrated by the significantly higher intestinal absorption of liposomal asiaticoside compared to unencapsulated CTG.

Shipping & Lead Time

Stock Orders: 3–5 business days after payment confirmation.

Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

Coverage: Worldwide shipping, including remote areas.